INDEMNIFICATION AGREEMENTIndemnification Agreement • June 23rd, 2014 • Immune Design Corp. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of , 2014, by and between Immune Design Corp., a Delaware corporation (the “Company”), and (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement and will become effective only upon the effectiveness of the Company’s registration statement on Form S-1 in connection with the Company’s initial public offering.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • June 23rd, 2014 • Immune Design Corp. • Pharmaceutical preparations • Delaware
LICENSE AGREEMENTLicense Agreement • June 23rd, 2014 • Immune Design Corp. • Pharmaceutical preparations • Delaware
THIS LICENSE AGREEMENT dated as of the 15th day of October, 2010 (the “Agreement”) is made between Immune Design Corp., a Delaware corporation having a place of business at 1124 Columbia Street, Suite 700, Seattle, Washington 98104 (“IDC’) and MedImmune, LLC, a Delaware limited liability company having its principal place of business at One MedImmune Way, Gaithersburg, Maryland 20878 (“MedImmune”).
LICENSE AGREEMENTLicense Agreement • June 23rd, 2014 • Immune Design Corp. • Pharmaceutical preparations • New York
This license agreement (“Agreement”) is entered into this 16th day of January, 2013 (the “Effective Date”) between The University of North Carolina at Chapel Hill having an address at Campus Box 4105, 308 Bynum Hall, Chapel Hill, North Carolina, 27599-4105 (“University”) and Immune Design Corporation, a corporation organized and existing under the laws of the State of Delaware having its principal office/place of business at 1124 Columbia Street, Suite 700, Seattle, WA 98104 (“Licensee”).
AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • June 23rd, 2014 • Immune Design Corp. • Pharmaceutical preparations • Washington
This Amended and Restated License Agreement (the “Agreement”) is made as of November 5, 2010 (the “Restated Effective Date”), to be effective as of July 10, 2008 (except as otherwise specified herein as to provisions effective as of the Restated Effective Date), by and between the Infectious Disease Research Institute, a Washington not-for-profit corporation having a place of business at 1124 Columbia Street, Suite 400, Seattle, Washington 98104 (“IDRI”), and Immune Design Corp., a Delaware corporation having a place of business at 1124 Columbia Street, Suite 402, Seattle, Washington, 98104 (“Immune Design”). IDRI and Immune Design are herein referred to individually as a “Party” and collectively as the “Parties.”
LICENSE AGREEMENTLicense Agreement • June 23rd, 2014 • Immune Design Corp. • Pharmaceutical preparations • California
THIS AGREEMENT is effective as of the 1st day of January 2009 (the “Effective Date”), between CALIFORNIA INSTITUTE OF TECHNOLOGY, 1200 East California Boulevard, Pasadena, CA 91125 (“Caltech”) and Immune Design Corp. (“Licensee”), a Delaware corporation having a place of business at 1124 Columbia Street, Suite 700, Seattle, WA, 98104. Each of Caltech and Licensee may be referred to herein as a “Party” and both as “Parties.”
SUBLEASE AGREEMENTLease Agreement • June 23rd, 2014 • Immune Design Corp. • Pharmaceutical preparations • Washington
This Sublease is made as of December 20, 2012, by and between THE BOARD OF REGENTS OF THE UNIVERSITY OF WASHINGTON, an agency of the State of Washington (“University”) and IMMUNE DESIGN CORP., a Delaware corporation (“IDC”).
ContractImmune Design Corp. • June 23rd, 2014 • Pharmaceutical preparations
*** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
